

**FINANCIAL STATEMENTS**

***Q3 2025***

**TAM DUC CARDIOLOGY HOSPITAL  
JOINT-STOCK COMPANY**



# CONTENTS

----- oOo -----

---

	Pages
1. BALANCE SHEET	01 - 04
2. INCOME STATEMENT	05
3. CASH FLOW STATEMENT	06 - 07
4. NOTES TO THE FINANCIAL STATEMENTS	08 - 31

---

**BALANCE SHEET***As at Sep 30, 2025**Unit: VND*

<b>ASSETS</b>	<b>Code</b>	<b>Notes</b>	<b>Sep. 30, 2025</b>	<b>Jan. 01, 2025</b>
<b>A. CURRENT ASSETS</b>	<b>100</b>		<b>249,184,316,723</b>	<b>236,952,381,558</b>
<b>I. Cash and cash equivalents</b>	<b>110</b>	<b>V.1</b>	<b>107,051,641,885</b>	<b>76,764,812,048</b>
1. Cash	111		37,051,641,885	31,764,812,048
2. Cash equivalents	112		70,000,000,000	45,000,000,000
<b>II. Short-term financial investments</b>	<b>120</b>		<b>67,077,004,732</b>	<b>97,077,004,732</b>
1. Trading securities	121		-	-
2. Provision for devaluation of trading securities	122		-	-
3. Held-to-maturity investments	123	V.2	67,077,004,732	97,077,004,732
<b>III. Short-term accounts receivables</b>	<b>130</b>		<b>25,249,436,528</b>	<b>22,271,657,679</b>
1. Current trade accounts receivables	131	V.3	3,493,394,188	4,086,600,931
2. Current prepayments to suppliers	132	V.4	1,729,436,416	6,501,118,570
3. Intercompany receivables	133		-	-
4. Receivables based on stages of construction contract schedule	134		-	-
5. Receivables from short-term loans	135		-	-
6. Other current receivables	136	V.5a	21,342,539,298	12,999,871,552
7. Provision for current doubtful debts	137	V.6	(1,315,933,374)	(1,315,933,374)
8. Shortage of assets awaiting resolution	139		-	-
<b>IV. Inventories</b>	<b>140</b>	<b>V.7</b>	<b>48,444,307,857</b>	<b>39,285,982,788</b>
1. Inventories	141		48,444,307,857	39,285,982,788
2. Provision for devaluation of inventories	149		-	-
<b>V. Other current assets</b>	<b>150</b>		<b>1,361,925,721</b>	<b>1,552,924,311</b>
1. Short-term prepaid expenses	151	V.10a	1,361,925,721	1,552,924,311
2. Deductible value added tax	152		-	-
3. Taxes and other receivables from the State Budget	153		-	-
4. Repurchase and sale of Government's bonds	154		-	-
5. Other current assets	155		-	-

**BALANCE SHEET**

As at Sep 30, 2025

Unit: VND

<b>ASSETS</b>	<b>Code</b>	<b>Notes</b>	<b>Sep. 30, 2025</b>	<b>Jan. 01, 2025</b>
<b>B. LONG-TERM ASSETS</b>	<b>200</b>		<b>167,277,287,632</b>	<b>155,778,265,662</b>
<b>I. Long-term receivables</b>	<b>210</b>		<b>222,244,540</b>	<b>22,244,540</b>
1. Long-term trade receivables	211		-	-
2. Long-term prepayments to suppliers	212		-	-
3. Working capital from sub-units	213		-	-
4. Long-term intercompany receivables	214		-	-
5. Receivables from long-term loans	215		-	-
6. Other long-term receivables	216	V.5b	222,244,540	22,244,540
7. Provision for doubtful long-term receivables	219		-	-
<b>II. Fixed assets</b>	<b>220</b>		<b>156,840,447,052</b>	<b>145,430,356,327</b>
1. Tangible fixed assets	221	V.8	152,259,395,731	140,703,694,960
- Cost	222		404,617,934,702	393,362,897,054
- Accumulated depreciation	223		(252,358,538,971)	(252,659,202,094)
2. Finance lease assets	224		-	-
- Cost	225		-	-
- Accumulated depreciation	226		-	-
3. Intangible fixed assets	227	V.9	4,581,051,321	4,726,661,367
- Cost	228		8,767,952,472	8,767,952,472
- Accumulated depreciation	229		(4,186,901,151)	(4,041,291,105)
<b>III. Investment Properties</b>	<b>230</b>		-	-
- Cost	231		-	-
- Accumulated depreciation	232		-	-
<b>IV. Long-term work in progress</b>	<b>240</b>		-	-
1. Long-term work in progress	241		-	-
2. Construction in progress	242		-	-
<b>V. Long-term investments</b>	<b>250</b>		-	-
1. Investments in subsidiaries	251		-	-
2. Investments in associates, joint-ventures	252		-	-
3. Investments in equity of other entities	253		-	-
4. Provision for decline in the value of long-term investments	254		-	-
5. Held-to-maturity investments	255		-	-
<b>VI. Other long-term assets</b>	<b>260</b>		<b>10,214,596,040</b>	<b>10,325,664,795</b>
1. Long-term prepaid expenses	261	V.10b	10,214,596,040	10,325,664,795
2. Deferred income tax assets	262		-	-
3. Long-term tools, supplies and spare parts	263		-	-
4. Other long-term assets	268		-	-
<b>TOTAL ASSETS</b>	<b>270</b>		<b>416,461,604,355</b>	<b>392,730,647,220</b>



**BALANCE SHEET***As at Sep 30, 2025**Unit: VND*

<b>RESOURCES</b>	<b>Code</b>	<b>Notes</b>	<b>Sep. 30, 2025</b>	<b>Jan. 01, 2025</b>
<b>C. LIABILITIES</b>	<b>300</b>		<b>81,843,854,811</b>	<b>68,613,220,800</b>
<b>I. Current liabilities</b>	<b>310</b>		<b>81,813,854,811</b>	<b>68,583,220,800</b>
1. Short-term trade payables	311	V.11	54,756,038,646	43,147,713,160
2. Prepayments from customers	312	V.12	2,656,885,962	1,495,013,481
3. Taxes and other payables to the State Budget	313	V.13	8,722,370,131	4,896,626,238
4. Payables to employees	314		8,030,000,000	11,345,590,603
5. Short-term accrued expenses	315	V.14	3,562,443,989	3,497,369,273
6. Short-term intercompany payables	316		-	-
7. Construction contract-in-progress payables	317		-	-
8. Short-term unrealized revenue	318		-	-
9. Other short-term payables	319	V.15a	3,934,691,083	4,102,683,045
10. Short-term borrowings and financial lease liabilities	320		-	-
11. Provision for short-term payables	321		-	-
12. Bonus and welfare fund	322		151,425,000	98,225,000
13. Price stabilization fund	323		-	-
14. Repurchase and sale of Government's bond	324		-	-
<b>II. Long-term liabilities</b>	<b>330</b>		<b>30,000,000</b>	<b>30,000,000</b>
1. Long-term trade payables	331		-	-
2. Long-term prepayments from customers	332		-	-
3. Long-term accrued expenses	333		-	-
4. Inter-company payables for operating capital received	334		-	-
5. Long-term intercompany payables	335		-	-
6. Long-term unrealized revenue	336		-	-
7. Other long-term payables	337	V.15b	30,000,000	30,000,000
8. Long-term borrowings and financial lease liabilities	338		-	-
9. Convertible bond	339		-	-
10. Preferred shares	340		-	-
11. Deferred income tax liabilities	341		-	-
12. Provision for long-term liabilities	342		-	-
13. Fund for science and technology development	343		-	-

**BALANCE SHEET**

As at Sep 30, 2025

Unit: VND

RESOURCES	Code	Notes	Sep. 30, 2025	Jan. 01, 2025
<b>D. OWNERS' EQUITY</b>	<b>400</b>		<b>334,617,749,544</b>	<b>324,117,426,420</b>
<b>I. Owners' equity</b>	<b>410</b>	<b>V.16</b>	<b>334,617,749,544</b>	<b>324,117,426,420</b>
1. Contributed capital	411		155,520,000,000	155,520,000,000
- Ordinary shares with voting rights	411a		155,520,000,000	155,520,000,000
- Preference shares	411b		-	-
2. Share premium	412		1,407,488,000	1,407,488,000
3. Bond conversion option	413		-	-
4. Owners' other capital	414		-	-
5. Treasury shares	415		-	-
6. Difference upon assets revaluation	416		-	-
7. Foreign exchange differences	417		-	-
8. Investment and development fund	418		16,603,467,737	16,603,467,737
9. Fund for support of arrangement of enterprises	419		-	-
10. Other funds	420		2,295,942,007	1,855,123,878
11. Undistributed earnings	421		158,790,851,800	148,731,346,805
- Undistributed earnings accumulated to the end of prior year	421a		111,079,136,805	87,355,323,686
- Undistributed earnings in this year	421b		47,711,714,995	61,376,023,119
12. Investment reserve for basic construction	422		-	-
<b>II. Budget sources and other funds</b>	<b>430</b>		-	-
1. Budget sources	431		-	-
2. Fund to form fixed assets	432		-	-
<b>TOTAL RESOURCES</b>	<b>440</b>		<b>416,461,604,355</b>	<b>392,730,647,220</b>

HCM City, Oct 18, 2025

PREPARED BY - THE CHIEF ACCOUNTANT



Phan Thi Thanh Nga, MBA

CHAIRMAN OF THE BOARD OF DIRECTORS



Dr. Nguyen Ngoc Chieu, MD, PhD



## INCOME STATEMENT

Q3 2025

Unit: VND

ITEMS	Code	Notes	Q3 2025		Cumulative from the beginning of the year to the end of this quarter	
			Q3 2025	Q3 2024	First 9 months of 2025	First 9 months of 2024
1. Sales	01	VI.1	211,066,362,880	199,653,365,592	611,240,428,359	566,396,362,341
2. Less sales deductions	02	VI.2	25,209,810	89,031,190	117,464,931	192,919,530
3. Net sales	10	VI.3	211,041,153,070	199,564,334,402	611,122,963,428	566,203,442,811
4. Cost of goods sold	11	VI.4	164,627,699,214	153,234,204,614	476,300,559,849	444,919,481,350
<b>5. Gross profit</b> (20 = 10 - 11)	<b>20</b>		<b>46,413,453,856</b>	<b>46,330,129,788</b>	<b>134,822,403,579</b>	<b>121,283,961,461</b>
6. Financial income	21	VI.5	834,539,110	488,436,879	4,011,531,563	2,509,244,030
7. Financial expense	22		-	-	-	-
<i>In which: loan interest expenses</i>	23		-	-	-	-
8. Selling expenses	25	VI.6a	3,373,380,891	3,824,882,719	10,151,802,400	11,667,806,074
9. General & administration expenses	26	VI.6b	16,752,945,641	16,019,005,417	51,264,209,510	48,320,507,239
<b>10. Operating profit</b> (30 = 20 + (21 - 22) - (25 + 26))	<b>30</b>		<b>27,121,666,434</b>	<b>26,974,678,531</b>	<b>77,417,923,232</b>	<b>63,804,892,178</b>
11. Other income	31	VI.7	928,119,599	461,159,496	1,737,155,237	2,023,694,448
12. Other expenses	32	VI.8	163,379,059	54,800,048	382,834,767	299,862,233
<b>13. Other profit (40 = 31 - 32)</b>	<b>40</b>		<b>764,740,540</b>	<b>406,359,448</b>	<b>1,354,320,470</b>	<b>1,723,832,215</b>
<b>14. Net accounting profit before tax</b> (50 = 30 + 40)	<b>50</b>		<b>27,886,406,974</b>	<b>27,381,037,979</b>	<b>78,772,243,702</b>	<b>65,528,724,393</b>
15. Corporate income tax - current	51	VI.10	3,067,942,954	3,075,529,976	8,666,184,578	7,360,405,998
16. Corporate income tax - deferred	52		-	-	-	-
<b>17. Net profit after corporate income tax</b> (60 = 50 - 51 - 52)	<b>60</b>		<b>24,818,464,020</b>	<b>24,305,508,003</b>	<b>70,106,059,124</b>	<b>58,168,318,395</b>
<b>18. Earnings per share</b>	<b>70</b>	<b>VI.11</b>	<b>1,482</b>	<b>1,450</b>	<b>4,177</b>	<b>3,437</b>
<b>19. Diluted earning per share</b>	<b>71</b>	<b>VI.12</b>	<b>1,482</b>	<b>1,450</b>	<b>4,177</b>	<b>3,437</b>

PREPARED BY - THE CHIEF ACCOUNTANT



Phan Thi Thanh Nga, MBA

HCM City, Oct 18, 2025

CHAIRMAN OF THE BOARD OF DIRECTORS



Dr. Nguyen Ngoc Chieu, MD, PhD

**CASH FLOW STATEMENT**

(Under indirect method)

Q3 2025

Unit: VND

ITEMS	Code	Notes	First 9 months of 2025	First 9 months of 2024
<b>I. CASH FLOW FROM OPERATING ACTIVITIES</b>				
<b>1. Net profit before tax</b>	01		<b>78,772,243,702</b>	<b>65,528,724,393</b>
<b>2. Adjustments for</b>				
- Depreciation of fixed assets and investment properties	02	V.8-9	15,287,602,744	14,895,353,282
- Provisions	03		-	-
- Gain/losses from foreign exchange differences upon revaluation of monetary assets denominated in foreign currencies	04	V.5	(154,102,712)	(117,129,677)
- Gain/losses from investing activities	05		(3,787,356,462)	(2,393,314,353)
- Interest expense	06		-	-
- Other adjustments	07		-	-
<b>3. Profit from operating activities before changes in working capital</b>	<b>08</b>		<b>90,118,387,272</b>	<b>77,913,633,645</b>
- Increase (-)/ decrease (+) in receivables	09		(4,378,778,849)	1,473,157,372
- Increase (-)/ decrease (+) in inventories	10		(9,158,325,069)	(1,441,666,891)
- Increase (-)/ decrease (+) in payables (Other than payables, income tax)	11		14,148,777,200	(143,876,773)
- Increase (-)/ decrease (+) in prepaid expenses	12		302,067,345	4,407,651,674
- Increase (-)/ decrease (+) in trading securities	13		-	-
- Interest paid	14		-	-
- Corporate income tax paid	15	V.13	(5,431,084,042)	(4,410,536,895)
- Other receipts from operating activities	16		87,219,706	640,063,435
- Other payments on operating activities	17		(5,554,800,000)	(5,390,775,000)
<b>Net cash inflows/(outflows) from operating activities</b>	<b>20</b>		<b>80,133,463,563</b>	<b>73,047,650,567</b>
<b>II. CASH FLOWS FROM INVESTING ACTIVITIES</b>				
1. Purchases of fixed assets and other long-term assets	21		(29,951,951,067)	(2,628,502,210)
Proceeds from disposals of fixed assets and other long-term assets	22		28,477,778	1,200,000
3. Loans granted, purchases of debt instruments of other entities	23		-	-
4. Collection of loans, proceeds from sales of debt instruments of other entities	24		30,000,000,000	-
5. Investments in other entities	25		-	-
6. Proceeds from divestment in other entities	26		-	-
7. Dividends and interest received	27		3,857,428,851	2,392,114,353
<b>Net cash inflows/(outflows) from investing activities</b>	<b>30</b>		<b>3,933,955,562</b>	<b>(235,187,857)</b>



**CASH FLOW STATEMENT**

(Under indirect method)

Q3 2025

Unit: VND

ITEMS	Code	Notes	First 9 months of 2025	First 9 months of 2024
<b>III. CASH FLOWS FROM FINANCING ACTIVITIES</b>				
1. Proceeds from issue of shares and capital contribution	31		-	-
2. Payments for shares returns and repurchases	32		-	-
3. Proceeds from borrowings	33		-	-
4. Repayments of borrowings	34		-	-
5. Payments for finance lease liabilities	35		-	-
6. Dividends paid	36		(53,934,692,000)	(53,720,422,600)
<b>Net cash inflows/(outflows) from financing activities</b>	<b>40</b>		<b>(53,934,692,000)</b>	<b>(53,720,422,600)</b>
<b>Net cash inflows/(outflows) (50 = 20+ 30 + 40)</b>	<b>50</b>		<b>30,132,727,125</b>	<b>19,092,040,110</b>
<b>Cash and cash equivalents at the beginning of the period</b>	<b>60</b>		<b>76,764,812,048</b>	<b>50,675,203,558</b>
Effect of foreign exchange differences	61		154,102,712	117,129,677
<b>Cash and cash equivalents at the end of the period (70 = 50+60+61)</b>	<b>70</b>	<b>V.1</b>	<b>107,051,641,885</b>	<b>69,884,373,345</b>

HCM City, Oct 18, 2025

PREPARED BY - THE CHIEF ACCOUNTANT



MBA. Phan Thi Thanh Nga

CHAIRMAN OF THE BOARD OF DIRECTORS



Dr. Nguyen Ngoc Chieu, MD, PhD

**NOTES TO THE FINANCIAL STATEMENTS**

Q3 2025

Unit: VND

**I. BUSINESS HIGHLIGHTS****1. Establishment**

Tam Duc Cardiology Hospital Joint-Stock Company (Hereinafter referred to as "The Company") is a Joint-Stock Company which is operating under the Business Registration Certificate No. 4103001109 issued by the Department of Planning and Investment of Ho Chi Minh City on July 16, 2002. Through various amendments to the business registration certificate, the Company is currently operating under the Business Registration Certificate No. 0302668322, amended for the 16th time on June 03, 2025, regarding additional information on charter capital and updating information on head office address. On September 16, 2016, the Minister of Health issued Medical Examination and Treatment Operation License No. 23/BYT-GPHD to Tam Duc Cardiology Hospital.

**English name:** TAM DUC CARDIOLOGY HOSPITAL JOINT STOCK COMPANY.

**Short name:** TAM DUC CO.

**Securities code:** TTD (Registered for trading on UpCom).

**Head office:** 04 Nguyen Luong Bang Street, Tan My Ward, Ho Chi Minh City.

**2. Business sector**

Public Joint Stock Company.

**3. Principal activities**

Medical examination and treatment services: hospital; Sale of medicine.

**4. Normal operating cycle**

Normal operating cycle of the Company lasts 12 months of the normal fiscal year beginning from January 01 and ending on December 31.

**5. Operations in the fiscal year affecting the financial statements:** Not applicable.**6. Total employees to September 30, 2025:** 535 employees. (December 31, 2024: 526 employees).**7. Disclosure on comparability of information in the Financial Statements**

The selection of figures and information need to be presented in the financial statements has been implemented on the principles of comparability among corresponding accounting periods.

**II. ACCOUNTING PERIOD AND REPORTING CURRENCY****1. Fiscal year**

The fiscal year is begun on January 01 and ended on December 31 annually.

**2. Reporting currency**

Vietnam Dong (VND) is used as a currency unit for accounting records.

**III. ADOPTION OF ACCOUNTING STANDARDS AND POLICIES****1. Applicable Accounting System**

The Company applies accounting standards, Vietnam Enterprise Accounting Regime issued under Circular No. 200/2014/TT-BTC dated December 22, 2014, Circular 53/2016/TT-BTC dated December 21 March 2016 amended and supplemented a number of articles of Circular 200/2014/TT-BTC and circulars guiding the implementation of accounting standards of the Ministry of Finance in preparing and presenting financial statements.

**2. Disclosure of compliance with Vietnamese Accounting Standards and the Vietnamese Accounting System**

The Board of Management ensures compliance with the requirements of Vietnamese accounting standards and the Vietnamese corporate accounting regime issued under Circular No. 200/2014/TT-BTC dated December 22, 2014, Circular 53/2016/TT-BTC dated March 21, 2016, amending and supplementing several articles of Circular 200/2014/TT-BTC as well as the circular guiding the implementation of accounting standards of the Ministry of Finance in preparation and presentation Financial report.



**NOTES TO THE FINANCIAL STATEMENTS**

Q3 2025

Unit: VND

**IV. APPLICABLE ACCOUNTING POLICIES****1. Basis for preparing financial statements**

Financial statements are prepared based on accrual accounting (except for information related to cash flows).

**2. Foreign exchange rate applicable in accounting**

The Company has translated foreign currencies into Vietnam Dong at the actual rate and book rate.

**Principles for determining the actual rate**

Transaction arising in foreign currencies are converted at the exchange rate at the date of the transaction. The balance of monetary items denominated in foreign currencies at the end of the accounting period are converted at the exchange rate on that date.

Exchange rate differences arising during the period from transactions in foreign currencies are recorded in financial income or financial expenses. Exchange rate differences due to revaluation of monetary items denominated in foreign currencies at the end of the accounting period clearing the increase and decrease difference are recorded in financial income or financial expenses.

**Principles for determining exchange rates for arising transactions**

The exchange rate used to convert transaction arising in foreign currency is the actual exchange rate at the time the transaction occurs. The actual exchange rate for transactions in foreign currency is determined as follows:

Actual exchange rate when foreign currencies are traded (foreign currencies spot contracts, forward contract): exchange rate stated in the foreign currencies trading contract signed between the Company and the bank.

**Principles for determining exchange rates at the end of the accounting period**

Closing balance of monetary items (cash, cash equivalents) denominated in foreign currencies should be revalued at the actual rate ruling as of the balance sheet date.

**3. Principles for recording cash and cash equivalents**

**Cash** includes cash on hand, demand deposit.

**Cash equivalents** comprise term deposits and other short-term investments with an original maturity of three months or less, highly liquid, readily convertible to known amount of cash and subject to an insignificant risk of changes in value.

**4. Principles for accounting financial investments****Principles for accounting held-to-maturity investment**

Held-to-maturity investments include term deposits held for earning purposes periodically.

Held-to-maturity investments are initially recorded at the original cost including buying price and costs attributable to the acquisition of the investments. After initial recognition, if the provision for doubtful debts has not been made as statutorily required, these investments are revalued at the recoverable value.

When there is solid evidence that part or all of the investment may not be recoverable, the loss is recorded in financial expenses in the period and recorded as a decrease in investment value.

**5. Principles for recording trade receivables and other receivables**

**Receivables** are presented at book value less provision for doubtful debts.

The classification of receivables is according to the following principles:

- **Receivables from customers** reflect commercial receivables arising from purchase-sale transactions between the Company and the buyers who are independent units of the Company.



## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

- **Other receivables** reflect non-commercial receivables, not related to purchase and sale transactions.

**Provision for doubtful debts** is made for each bad debt based on the overdue age of the debts or the expected amount loss that may occur, specifically as follows:

- For overdue receivables: The company estimates the portion of lost value and sets up provisions in accordance with current regulations.

- For receivables that are not overdue but are unlikely to be recovered: base on the expected level of loss to set up provisions.

Increases and decreases in doubtful debt provision balances that need to be appropriated at the end of the accounting period are recorded in corporate management expenses.

## 6. Principles for recording inventories

Inventories are recorded at the lower of cost and net realizable value.

**The original costs are determined as follows**

**Raw materials, tools, goods:** includes purchasing costs and other directly related costs incurred to bring inventory to its current location and condition.

**Method of calculating inventories' value:** FIFO.

**Method of accounting for the inventories:** Perpetual method.

**Method for setting up provisions for devaluation of inventory:** Provision for devaluation of inventory is established for each inventory item whose original price is greater than its net realizable value. Net realizable value is the estimated selling price of inventories in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to consume them.

Increases and decreases in the balances of provision for devaluation of inventory that need to be appropriated at the end of the accounting period are recorded in cost of goods sold.

## 7. Principles for recording fixed assets

### 7.1 Principles for recording tangible fixed assets

Tangible fixed assets are stated at original cost less (-) accumulated depreciation. The initial cost of a tangible fixed asset comprises all expenditures of bringing the asset to its working condition and location for its intended use. The expenditures incurred beyond their originally assessed standard of performance are capitalized as an additional cost of tangible fixed assets when they have resulted in an increase in the future economic benefits expected to be obtained from the use of those tangible fixed assets. The expenditures which do not meet the above conditions are charged to the expenses in the period.

When the assets are sold or disposed, their original costs and the accumulated depreciation which have been written off and any gain or loss from disposal of assets are recorded in the income statement.

Determination of original costs of tangible fixed assets:

*Tangible fixed assets purchased*

The original cost of purchased tangible fixed assets shall consist of the actual purchase price less (-) trade discounts or reduction plus (+) taxes (excluding taxes to be refunded) and relevant expenses calculated to the time when such fixed assets are put into operation such as fees for installation and trial operation of fixed assets; specialists and other direct costs.

The original cost of a tangible fixed asset formed from capital construction under the mode of tendering shall be the finalisation price of the construction project, other relevant fees plus (+) registration fee (if any).

Fixed assets which are buildings, structures attached to land use right, the value of land use right is computed separately and recorded as intangible fixed assets.

*Purchase of fixed assets being attached with equipment, spare parts for replacement*



**NOTES TO THE FINANCIAL STATEMENTS**

Q3 2025

Unit: VND

When buying fixed assets if goods, equipment or spare parts for replacement are attached, the changeable goods, equipment or accessories shall be recorded separately according to the fair value. The original cost of the purchased fixed assets includes all expenditures of bringing the asset to its working condition minus (-) value of changeable goods, equipment or spare parts for replacement.

**7.2 Principles for recording intangible fixed assets:**

**Intangible fixed assets** are stated at original cost less (-) accumulated depreciation. The original cost of a intangible fixed asset comprises all costs of owning the asset to the date it is put into operation as expected.

Principles for recording intangible fixed assets

*Purchase separate intangible fixed assets*

The original cost of purchased intangible fixed assets shall consist of the actual purchase price payable less (-) trade discounts or reduction plus (+) taxes (excluding taxes to be refunded) and relevant expenses calculated to the time when such fixed assets are put into operation. The land use rights, which are purchased together with buildings, structures, will be determined separately and recorded as intangible fixed assets.

*Land use right*

Land use rights are all actual expenses the Company has paid that are directly related to used land, including: money spent to have land use rights, costs for compensation and site clearance, site leveling, registration fees, etc. When land use rights are purchased along with houses and architectural objects on the land, the value of land use rights is determined separately and recorded as intangible fixed assets.

*Software program*

Costs related to computer software programs that are not an integral part of the related hardware are capitalized. The original price of computer software is all expenses that the Company has spent up to the time the software is put into use.

**7.3 Method of depreciating and amortizing fixed assets**

Fixed assets are depreciated using the straight-line method over the estimated useful life of the asset. Estimated useful life is the time during which the asset is effective for production and business.

***The estimated useful life for assets is as follows:***

<i>Buildings and structures</i>	<i>10-30 years</i>
<i>Machinery and equipment</i>	<i>5-15 years</i>
<i>Transportation and facilities</i>	<i>9-10 years</i>
<i>Office equipment</i>	<i>7-12 years</i>
<i>Land use rights (Depreciation started from 2011) (*)</i>	<i>42 years</i>
<i>Software program</i>	<i>2-10 years</i>

(\*) Land use rights which are granted for a definite term are amortized in conformity with the term stated in the certificate of land use right.

**8. Principles for recording prepaid expenses**

Prepaid expenses at the Company include actual expenses that have been incurred but are related to business results of many accounting periods. Method of allocating prepaid expenses: The calculating and allocating of prepaid expenses to business operating expenses of each period are according to the straight-line method.

The company's prepaid expenses include the following expenses:

**Tools and supplies:** Tools and supplies already put into use are allocated to expenses according to the straight-line method with an allocation period of no more than 36 months.

**Fixed asset repair costs:** One-time asset repair costs of high value are allocated to expenses according to the straight-line method over 36 months.



**NOTES TO THE FINANCIAL STATEMENTS**

Q3 2025

Unit: VND

**Insurance costs (accident insurance, car insurance, property insurance...) and other costs:** Costs that already put into use are allocated to expenses according to the straight-line method with the allocation period according to the usage time on the contract.

**9. Principle of recording payables**

Liabilities are recognized for amounts to be paid in the future for goods and services received. Accrued expenses are recognized based on reasonable estimates of the amount payable.

The classification of payables as trade payables, accrued expenses and other payables is made according to the following principles:

- **Trade payables** reflect trade payables arising from transactions of purchasing goods, services, assets and the seller is an independent unit of the Company.
- **Other payables** reflect non-commercial payables, not related to transactions of purchasing, selling or providing with goods and services.

**10. Principles for recording accrued expenses**

Accrued expenses include electricity, water, testing,... which have arisen in the reporting period, but have not been settled. These costs are recognised on the basis of reasonable estimates on the amounts to be paid in accordance with specific contracts, agreements, and reconciliation minutes.

**11. Principles for recording owner's Equity****Principles for recording owners' paid-in capital**

Owner's contributed capital is recorded according to the actual amount of capital contributed by shareholders.

**Share premium:** Share premium is recorded according to the difference between the issue price and par value of shares when being initially issued, additionally issued, the difference between re-issue price and book value of treasury shares and capital components of convertible bonds at maturity. Direct costs related to the issuance of additional shares and re-issuance of treasury shares are recorded as a decrease in share premium.

**Principles for recognising undistributed profit**

Profit after corporate income tax is distributed to shareholders after setting up funds according to the Charter of the Company as well as the provisions of law and approved by the General Meeting of Shareholders.

The distribution of profits to owners/shareholders/members which takes into account non-monetary items included in undistributed after-tax profits may affect cash flow and ability to pay dividends such as profits due to revaluation of assets contributed as capital, profits due to revaluation of monetary items, financial instruments and other non-monetary items.

Dividends are recognized as liabilities when approved by the General Meeting of Shareholders.

**12. Principles and methods of recording Revenue and other income****Principles and methods of recording sales revenue**

Sales revenue is recognized when the following five (5) conditions are simultaneously met: 1. The enterprise has transferred most of the risks and benefits associated with ownership of the product or goods to the buyer; 2. The enterprise no longer holds the right to manage the goods as the owner of the goods or the right to control the goods; 3. Revenue is measured with relative certainty. When the contract stipulates that the buyer has the right to return the purchased products or goods under specific conditions, revenue is only recognized when those specific conditions no longer exist and the buyer is not entitled to return the products and goods (except in cases where customers have the right to return goods in the form of exchange for other goods or services); 4. The enterprise receives or will receive economic benefits from the sales transaction; 5. Costs related to sales transactions can be identified.



**NOTES TO THE FINANCIAL STATEMENTS**

Q3 2025

Unit: VND

**Principles and methods of recording service provision revenue**

Revenue from a service provision transaction is recognized when the outcome of that transaction can be determined reliably. In case the service is performed in many periods, the revenue recognized in the period is based on the results of the work completed at the end of the accounting period.

The results of a service provision transaction are determined when all four (4) conditions are met: 1. Revenue can be determined with relative certainty. When the contract stipulates that the buyer is entitled to return the purchased services under specific conditions, revenue is recognized only when those specific conditions no longer exist and the buyer is not entitled to return the purchased services; 2. Economic benefits from the transaction providing that service can be obtained; 3. The work completed at the end of the accounting period can be determined; 4. The costs incurred for the transaction and the costs to complete the service provision transaction can be determined.

**Principles and methods of recording financial income**

Income arising from interests of the enterprise shall be recognized when two conditions are simultaneously satisfied: 1. It is possible to gain benefits from that transaction; 2. Revenue is determined with relative certainty.

Revenue from financial activities includes: interest and revenue from other financial activities of the enterprise.

**Interest** is recorded on an accrual basis, determined on the balance of deposit accounts and the actual interest rate each period.

When an amount which has been recorded as an income becomes irrecoverable, such irrecoverable or uncertainly recoverable amount must be accounted as expense incurred in the period, but not recorded as income decrease.

**13. Principles and methods of recording cost of goods sold**

Cost of goods sold are the cost of products, goods, services sold in the period; expenses related to trading the investment properties and other expenses recorded in the cost of goods sold or recorded a decrease in the cost of goods sold in the reporting period. The cost of goods sold is recorded at the date the transaction incurs or likely to incur in the future regardless of payment has been made or not. The cost of goods sold and revenue shall be recorded simultaneously on conformity principles. Expenses exceeding normal consumption levels are recorded immediately to the cost of goods sold on prudent principles.

**14. Principles and methods of recording current corporate income tax expenses and deferred corporate income tax expenses**

Corporate income tax includes current corporate income tax and deferred corporate income tax incurred in the year and set basis for determining operating result after tax in current fiscal year.

Current income tax is a tax calculated based on taxable income. Taxable income differs from accounting profit due to adjustment of temporary differences between tax and accounting, non-deductible expenses as well as adjustment of non-taxable income and transferred losses.

The tax amounts payable to the State budget will be finalized with the tax office. Differences between the tax amounts payable specified in the book and the tax amounts under finalization will be adjusted when the tax finalization has been issued by the tax office.

Tax policies the Company should comply with are as follows:

Taxable income from medical examination and treatment services enjoys a preferential tax rate of 10% throughout the operating period, while income other than medical examination and treatment services is subject to the normal tax rate of 20%.

The Company has finalized its tax to the year 2016.



**NOTES TO THE FINANCIAL STATEMENTS**

Q3 2025

Unit: VND

**15. Principle of recording earnings per share**

Basic earnings per share are calculated by dividing the profit or loss attributable to common shareholders of the Company after deducting the Bonus and Welfare Fund, Charity Fund, Humanitarian Fund, Board of Directors and Supervisory Board Activities Fund established during the period by the weighted-average number of common shares outstanding during the period.

Diluted earnings per share are calculated by dividing the profit or loss after tax attributable to common shareholders of the Company (after adjusting for dividends on convertible preference shares) by the weighted-average number of common shares outstanding and the weighted-average number to be issued in a case where all dilutive potential common shares are converted into common shares.

**16. Financial instruments****Initial recognition****Financial assets**

According to Circular No. 210/2009/TT-BTC dated November 06, 2009 (Circular No. 210), financial assets are classified properly, for the purpose of presentation in the financial statements, into the financial assets which are stated at fair value through the Income Statement, loans and receivables, held-to-maturity investments and available-for-sale financial assets. The Company decides to classify these assets at the date of initial recognition.

At the date of initial recognition, the financial assets are recognized at cost plus transaction cost that are directly attributable to the acquisition of the financial assets.

Financial assets of the Company comprise cash, short-term deposits, trade accounts receivables and other receivables.

**Financial liabilities**

According to Circular 210, financial liabilities are classified properly, for the purpose of presentation in the financial statements, into the financial liabilities which are stated at fair value through the Income Statement, financial liabilities determined on amortised cost basis. The Company decides to classify these liabilities at the date of initial recognition.

At the date of initial recognition, the financial liabilities are recognized at cost plus transaction cost that are directly attributable to the acquisition of the financial liabilities.

Financial liabilities of the Company comprise trade payables, accrued expenses, and other payables.

**Re-measurements after initial recognition**

Currently, there are no requirements for the re-measurement of the financial instruments after initial recognition.

**Offsetting**

Financial assets and financial liabilities are offset and the net amount reported in the report on financial position if, and only if, there is a currently enforceable legal right to offset the financial assets against financial liabilities or vice-versa and there is an intention to settle on a net basis or to realize the assets and settle the liability simultaneously.

**17. Related parties**

(i) Individuals with direct or indirect voting rights in enterprises that lead to significant influence over these enterprises, including close family members of these individuals. Close family members of an individual are those who can control or be controlled by that person when dealing with a business such as: Father, mother, spouses, children, siblings;

(ii) Key management employees have the rights and responsibilities for planning, managing and controlling the activities of the Company, including leaders and management staff of the company and close family members of these individuals;

(iii) Enterprises where the individuals mentioned in case (i) or case (ii) of this article directly or indirectly hold an important part of the voting rights, or through this, that person can have a significant impact on the business. This includes businesses that are owned by the directors or major shareholders of the Company and businesses that share a key member of management with the Company.



## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

## V. ADDITIONAL INFORMATION FOR ITEMS SHOWN IN THE BALANCE SHEET

1. Cash and cash equivalents	Sep. 30, 2025	Jan. 01, 2025
<b>Cash</b>	<b>37,051,641,885</b>	<b>31,764,812,048</b>
Cash on hand	448,028,873	333,700,424
Demand deposit	36,603,613,012	31,431,111,624
+ VND	33,462,266,777	28,444,860,419
Argibank	1,015,008,371	13,741,977,603
Vietcombank	32,447,258,406	14,702,882,816
+ Foreign currency	3,141,346,235	2,986,251,205
Vietcombank - USD	2,457,828,640	2,395,567,168
Vietcombank - EUR	683,517,595	590,684,037
<b>Cash equivalents</b>	<b>70,000,000,000</b>	<b>45,000,000,000</b>
Term deposits of no more than 3 months (*)	70,000,000,000	45,000,000,000
<b>Total</b>	<b>107,051,641,885</b>	<b>76,764,812,048</b>

(\*) As at September 30, 2025, cash equivalents are deposit contracts with terms of 03 months at joint stock commercial banks with interest rates ranging from 4.0% - 4.3%/year.

## 2. Held-to-maturity investments

	Sep. 30, 2025		Jan. 01, 2025	
Short term	Original price	Book value	Original price	Book value
Term deposit (*)	67,077,004,732	67,077,004,732	97,077,004,732	97,077,004,732
<b>Total</b>	<b>67,077,004,732</b>	<b>67,077,004,732</b>	<b>97,077,004,732</b>	<b>97,077,004,732</b>

(\*) As at September 30, 2025, short term held to maturity investments are deposit contracts with terms of 06 - 12 months at joint stock commercial banks with interest rates ranging from 4.1% - 4.8%/year.

## 3. Trade receivables

	Sep. 30, 2025		Jan. 01, 2025	
Short term	Amount	Provision	Amount	Provision
Local customers	3,493,394,188	(1,315,933,374)	4,086,600,931	(1,315,933,374)
Ho Chi Minh City Association for the Support of Poor Patients	183,790,720	-	446,199,481	-
VietNam Children's Fund Social Enterprise Company Limited	27,179,680	-	176,133,780	-
Other customers	3,282,423,788	(1,315,933,374)	3,464,267,670	(1,315,933,374)
<b>Total</b>	<b>3,493,394,188</b>	<b>(1,315,933,374)</b>	<b>4,086,600,931</b>	<b>(1,315,933,374)</b>

## 4. Prepayments to suppliers

	Sep. 30, 2025		Jan. 01, 2025	
Short term	Amount	Provision	Amount	Provision
Local suppliers	1,729,436,416	-	6,501,118,570	-
Minh Khoa Technologies Co., Ltd	1,201,000,000	-	-	-
Sai Gon Gia Dinh Garment Co., Ltd	311,785,848	-	-	-

## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

TRAMAT Co., Ltd.	-	-	5,994,000,000	-
Other local suppliers	216,650,568	-	507,118,570	-
<b>Total</b>	<b>1,729,436,416</b>	<b>-</b>	<b>6,501,118,570</b>	<b>-</b>
<b>5. Other receivables</b>	<b>Sep. 30, 2025</b>		<b>Jan. 01, 2025</b>	
	<b>Amount</b>	<b>Provision</b>	<b>Amount</b>	<b>Provision</b>
<b>a. Short-term</b>	<b>21,342,539,298</b>	<b>-</b>	<b>12,999,871,552</b>	<b>-</b>
Receivables from employees	310,810,120	-	189,942,000	-
Deposits	243,965,000	-	243,965,000	-
Payment on behalf of Health Insurance (*)	19,977,092,769	-	10,916,519,680	-
Interest on deposits expected to be collected	575,036,589	-	1,336,685,095	-
Other receivables	235,634,820	-	312,759,777	-
<b>b. Long-term</b>	<b>222,244,540</b>	<b>-</b>	<b>22,244,540</b>	<b>-</b>
Deposits	222,244,540	-	22,244,540	-
<b>Total</b>	<b>21,564,783,838</b>	<b>-</b>	<b>13,022,116,092</b>	<b>-</b>

(\*) These are medical examination and treatment expenses for patients using Health Insurance cards. This receivable will be settled with the Ho Chi Minh City Social Insurance agency.

## 6. Overdue debts with provisions (See page 28).

<b>7. Inventory</b>	<b>Sep. 30, 2025</b>		<b>Jan. 01, 2025</b>	
	<b>Original price</b>	<b>Provision</b>	<b>Original price</b>	<b>Provision</b>
Raw materials	28,984,854,984	-	24,627,459,062	-
Tools and Instrument	1,334,145,290	-	1,469,467,258	-
Goods	18,125,307,583	-	13,189,056,468	-
<b>Total</b>	<b>48,444,307,857</b>	<b>-</b>	<b>39,285,982,788</b>	<b>-</b>

- Value of inactive, deteriorated inventories which are not possibly consumed at the period end: Not applicable.

- The carrying amount of inventories pledged as security for liabilities: Not applicable.

## 8. Tangible fixed assets (See page 29).

## 9. Intangible fixed assets

Items	Land use rights (*)	Software program	Total
<b>Original cost</b>			
Balance as at Jan. 01, 2025	6,970,212,772	1,797,739,700	8,767,952,472
Balance as at Sep. 30, 2025	6,970,212,772	1,797,739,700	8,767,952,472
<b>Accumulated depreciation</b>			
Balance as at Jan. 01, 2025	2,323,404,216	1,717,886,889	4,041,291,105
Charge during the period	124,468,083	21,141,963	145,610,046
Balance as at Sep. 30, 2025	2,447,872,299	1,739,028,852	4,186,901,151



## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

## Net book value

Balance as at Jan. 01, 2025	4,646,808,556	79,852,811	4,726,661,367
Balance as at Sep. 30, 2025	4,522,340,473	58,710,848	4,581,051,321

- Ending carrying value of intangible fixed assets pledged/mortgaged as loan security: Not applicable.
- Ending original costs of intangible fixed assets—fully depreciated but still in use: 1,583,539,700 VND.
- Commitments on tangible fixed assets acquisitions, sales of large value in the future: Not applicable.

\* According to the Certificate of Land Use Rights No. CT 35912, the area of Area 1 is 10,000 m<sup>2</sup>, address at No. 04 Quarter 1 Nguyen Luong Bang, Tan My Ward, HCM City. Expiry date until May 02, 2053.

10. Prepaid expenses	Sep. 30, 2025	Jan. 01, 2025
<b>a. Short-term prepaid expenses</b>	<b>1,361,925,721</b>	<b>1,552,924,311</b>
Software maintenance, insurance,...	1,361,925,721	1,552,924,311
<b>b. Long-term prepaid expenses</b>	<b>10,214,596,040</b>	<b>10,325,664,795</b>
Tools and supplies awaiting allocation	2,338,144,475	2,543,695,502
Machinery maintenance, repairing hospital facilities, ...	7,876,451,565	7,781,969,293
<b>Total</b>	<b>11,576,521,761</b>	<b>11,878,589,106</b>

11. Trade payables	Sep. 30, 2025		Jan. 01, 2025	
	Amount	Debts Service Coverage	Amount	Debts Service Coverage
<b>Short-term</b>	<b>54,756,038,646</b>	<b>54,756,038,646</b>	<b>43,147,713,160</b>	<b>43,147,713,160</b>
Local suppliers	54,756,038,646	54,756,038,646	43,147,713,160	43,147,713,160
TRAMAT Co., Ltd.	6,972,000,000	6,972,000,000	-	-
National Phytopharma JSC (Phytopharma)	3,818,310,159	3,818,310,159	4,474,992,106	4,474,992,106
Trieu Giang Pharmaceutical Co., Ltd	6,674,867,304	6,674,867,304	6,318,916,478	6,318,916,478
Other local suppliers	37,290,861,183	37,290,861,183	32,353,804,576	32,353,804,576
<b>Total</b>	<b>54,756,038,646</b>	<b>54,756,038,646</b>	<b>43,147,713,160</b>	<b>43,147,713,160</b>

12. Prepayments from customers	Sep. 30, 2025	Jan. 01, 2025
Local customers	2,656,885,962	1,495,013,481
Advances from patients	1,289,199,741	589,342,170
Benefactor association	532,739,245	148,923,370
Other local customers	834,946,976	756,747,941
<b>Total</b>	<b>2,656,885,962</b>	<b>1,495,013,481</b>

## 13. Taxes and payables to the State Budget

Payables	Jan. 01, 2025	Payable amount	Paid amount	Sep. 30, 2025
Value added tax	160,413,995	1,176,723,203	425,104,965	912,032,233
Corporate income tax	3,382,945,231	8,666,184,578	5,431,084,042	6,618,045,767
Personal income tax	1,353,267,012	14,117,057,736	14,278,032,617	1,192,292,131
Other taxes	-	3,000,000	3,000,000	-
<b>Total</b>	<b>4,896,626,238</b>	<b>23,962,965,517</b>	<b>20,137,221,624</b>	<b>8,722,370,131</b>

Present methods for determining taxes, fees, and levies to be paid

## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

**Value added tax**

The company pays value added tax using the deduction method. Value added tax rate are as follows:

	<b>Tax rate</b>
- VAT rate on outpatient medical examination and treatment, inpatient hospital fees	<b>Not subject to tax</b>
- VAT rate on medicine	<b>5%</b>
- VAT rate other than outpatient medical examination and treatment services and medicine	<b>10%</b>

*In the third quarter of 2025, The company is entitled to a reduced VAT rate of 8% according to Decree No. 174/2025/NĐ-CP dated June 30, 2025, applicable from July 1, 2025, to December 31, 2026.*

**Corporate income tax**

Taxable income from medical examination and treatment services enjoys a preferential tax rate of 10% throughout the operating period, while income from other medical examination and treatment services is still subject to the normal tax rate of 20%.

**Land rental**

The company must pay land rent for the land areas currently in use at the following rent rates:

<b>Land location</b>	<b>Rent rate</b>
Nguyen Dong Chi, Tan My Ward, HCM City (5,000 m <sup>2</sup> )	414,180 VND/m <sup>2</sup>

**Other taxes**

The Company declares and pays as statutorily required.

	<b>Sep. 30, 2025</b>	<b>Jan. 01, 2025</b>
<b>14. Short-term payables</b>		
Cost of medical waste and household waste treatment	299,165,919	351,926,604
Cost of sending test samples	837,141,000	667,270,000
Advance payment of land rental	931,905,000	-
Expenses payable (electricity, water, testing, specialized machine maintenance, received goods without invoices...)	1,494,232,070	2,478,172,669
<b>Total</b>	<b>3,562,443,989</b>	<b>3,497,369,273</b>
<b>15. Other payables</b>		
<b>a. Short-term</b>	<b>3,934,691,083</b>	<b>4,102,683,045</b>
SHUI, trade union fees	19,718,567	20,467,692
Keeping patient support funds of organizations and individuals	1,227,166,857	1,154,761,462
Collection and payment on behalf of sponsored research contracts and conferences	1,540,263,695	1,550,449,384
Other payables	1,147,541,964	1,377,004,507
<b>b. Long-term</b>	<b>30,000,000</b>	<b>30,000,000</b>
Receipt of deposits	30,000,000	30,000,000
<b>Total</b>	<b>3,964,691,083</b>	<b>4,132,683,045</b>

**16. Owners' equity****a. Comparison schedule for changes in Owners's Equity (See page 30).**



## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

## 16. Owners' equity (cont.)

b. Details of owners' shareholding	Sep. 30, 2025		Jan. 01, 2025	
	Capital contribution	Capital contribution ratio	Capital contribution	Capital contribution ratio
Ms. Nguyen Thi Hanh	15,552,000,000	10.00%	15,552,000,000	10.00%
Ms. Nguyen Thi Thu Hong	12,350,000,000	7.94%	12,350,000,000	7.94%
An Viet Hung Investment Joint Stock Company	12,062,600,000	7.76%	12,062,600,000	7.76%
Capital contributions from other investors	115,555,400,000	74.30%	115,555,400,000	74.30%
<b>Total</b>	<b>155,520,000,000</b>	<b>100%</b>	<b>155,520,000,000</b>	<b>100%</b>
<b>c. Capital transactions with owners and distribution of dividends, profits</b>			<b>First 9 months of 2025</b>	<b>First 9 months of 2024</b>
Owners' equity			<b>155,520,000,000</b>	<b>155,520,000,000</b>
<i>At the beginning of the period</i>			<i>155,520,000,000</i>	<i>155,520,000,000</i>
<i>At the end of the period</i>			<i>155,520,000,000</i>	<i>155,520,000,000</i>
Dividends distributed			<b>54,022,736,000</b>	<b>54,022,736,000</b>
<b>e. Shares</b>			<b>Sep. 30, 2025</b>	<b>Jan. 01, 2025</b>
Number of shares registered to be issued			15,552,000	15,552,000
Number of shares sold out to the public			15,552,000	15,552,000
<i>Ordinary share</i>			<i>15,552,000</i>	<i>15,552,000</i>
Number of existing shares in issue			15,552,000	15,552,000
<i>Ordinary share</i>			<i>15,552,000</i>	<i>15,552,000</i>
<i>Par value: VND/share</i>			<i>10,000</i>	<i>10,000</i>
<b>f. Funds</b>			<b>Sep. 30, 2025</b>	<b>Jan. 01, 2025</b>
Investment and development fund			16,603,467,737	16,603,467,737
Other Funds			2,295,942,007	1,855,123,878
<b>Total</b>			<b>18,899,409,744</b>	<b>18,458,591,615</b>

\* Purpose of appropriating and using funds

*Investment and development fund is established from the profit after tax of the enterprise and used for expanding the operating scale or investing further in the enterprise .*

## 17. Off balance sheet items

a. Assets held under trust	Unit	Quantity	
		Sep. 30, 2025	Jan. 01, 2025
Consigned materials			
<i>Amplatez/Coil</i>	<i>Pcs</i>	9	31
<i>Amplatez/Coil</i>	<i>Set</i>	3	4
<i>Anneaux</i>	<i>Pcs</i>	16	15
<i>Ballon</i>	<i>Pcs</i>	487	520

## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

Electrophysiology Instruments	Pcs	113	50
Electrophysiology Instruments	Set	14	41
Pacemaker	Pcs	27	2
Pacemaker	Set	3	6
Stent	Pcs	430	388
Valve	Pcs	54	55
Medical Instruments	Set	10	7
Medical Instruments	Pcs	45	44
<b>Total</b>		<b>1,211</b>	<b>1,163</b>

## b. Foreign currencies

	Sep. 30, 2025		Jan. 01, 2025	
	Original currency	Value (VND)	Original currency	Value (VND)
USD	\$ 94,860.29	2,457,828,640	\$ 94,870.19	2,395,567,168
EUR	€ 22,687.61	683,517,595	€ 22,645.88	590,684,037
<b>Total</b>		<b>3,141,346,235</b>		<b>2,986,251,205</b>

## VI. ADDITIONAL INFORMATION FOR ITEMS IN THE INCOME STATEMENT

	Q3 2025	Q3 2024
<b>1. Sales</b>		
Revenue from medical examinations and treatments	152,295,252,454	148,025,036,771
Revenue from drug sales	58,557,721,538	51,086,422,310
Other revenues	213,388,888	541,906,511
<b>Total</b>	<b>211,066,362,880</b>	<b>199,653,365,592</b>
<b>2. Sales deductions</b>	<b>Q3 2025</b>	<b>Q3 2024</b>
Sales returns	25,209,810	89,031,190
<b>Total</b>	<b>25,209,810</b>	<b>89,031,190</b>
<b>3. Net sales</b>	<b>Q3 2025</b>	<b>Q3 2024</b>
Revenue from medical examinations and treatments	152,295,252,454	148,025,036,771
Revenue from drug sales	58,532,511,728	50,997,391,120
Other revenues	213,388,888	541,906,511
<b>Total</b>	<b>211,041,153,070</b>	<b>199,564,334,402</b>
<b>4. Cost of goods sold</b>	<b>Q3 2025</b>	<b>Q3 2024</b>
Cost of medical examination and treatment services	112,713,947,132	106,525,177,043
Cost of drug sales	51,663,127,082	43,975,631,323
Cost of other activities	250,625,000	2,733,396,248
<b>Total</b>	<b>164,627,699,214</b>	<b>153,234,204,614</b>
<b>5. Financial income</b>	<b>Q3 2025</b>	<b>Q3 2024</b>
Interest income from deposits	834,539,110	488,436,879
<b>Total</b>	<b>834,539,110</b>	<b>488,436,879</b>



## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

6. Selling expenses and General and administration expenses	Q3 2025	Q3 2024
<b>a. Selling expenses</b>		
Salaries	1,371,589,914	1,815,153,950
Materials and packaging	274,148,258	282,392,525
Tools and supplies	941,666	33,465,891
Depreciation	3,065,970	3,065,970
Services bought from outsiders	1,600,490,254	1,572,526,432
Other expenses	123,144,829	118,277,951
<b>Total</b>	<b>3,373,380,891</b>	<b>3,824,882,719</b>
<b>b. General and administration expenses</b>		
Salaries	10,620,808,296	9,581,105,159
Materials and packaging	178,703,025	197,810,274
Tools and supplies	357,499,556	375,699,432
Depreciation	1,560,707,899	1,599,172,145
Taxes, fees and duties	(103,545,000)	517,725,000
Services bought from outsiders	3,431,331,596	3,115,798,055
Other expenses	707,440,269	631,695,352
<b>Total</b>	<b>16,752,945,641</b>	<b>16,019,005,417</b>
<b>7. Other income</b>	<b>Q3 2025</b>	<b>Q3 2024</b>
Income from leasing shops, convenience store premises, halls, etc.	525,532,818	400,632,103
Other income	402,586,781	60,527,393
<b>Total</b>	<b>928,119,599</b>	<b>461,159,496</b>
<b>8. Other expenses</b>	<b>Q3 2025</b>	<b>Q3 2024</b>
Liquidation of damaged and expired drugs and materials	546,700	-
Fine amount	546,604	-
Other expenses	162,285,755	54,800,048
<b>Total</b>	<b>163,379,059</b>	<b>54,800,048</b>
<b>9. Costs of production and doing business by factors</b>	<b>Q3 2025</b>	<b>Q3 2024</b>
Raw materials	114,359,626,531	106,820,651,539
Labour cost	46,218,605,221	44,881,614,856
Depreciation and amortization	5,238,051,495	4,984,413,199
Services bought from outsiders	10,591,946,266	8,907,826,447
Other expenses	8,345,796,233	7,483,586,709
<b>Total</b>	<b>184,754,025,746</b>	<b>173,078,092,750</b>
<b>10. Current corporate income tax</b>	<b>Q3 2025</b>	<b>Q3 2024</b>
1. Corporate income tax liabilities calculated on taxable income of current year	3,067,942,954	3,075,529,976
<b>2. Total Current corporate income tax</b>	<b>3,067,942,954</b>	<b>3,075,529,976</b>



## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

11. Earning per share	Q3 2025	Q3 2024
Accounting profit after corporate income tax	24,818,464,020	24,305,508,003
Increase or decrease adjustments	(1,768,464,705)	(1,749,998,288)
- Bonus, welfare and other funds	(1,768,464,705)	(1,749,998,288)
Profit or loss attributable to ordinary equity holders	23,049,999,315	22,555,509,715
Average ordinary shares outstanding during the period	15,552,000	15,552,000
Earnings per share	<u>1,482</u>	<u>1,450</u>
12. Diluted earning per share	Q3 2025	Q3 2024
Profit or loss allocated to shareholders owning ordinary shares	23,049,999,315	22,555,509,715
Profit or loss allocated to shareholders owning ordinary shares after adjusting dilution factors	23,049,999,315	22,555,509,715
Average outstanding ordinary shares in the period	15,552,000	15,552,000
Average outstanding ordinary shares in the period after adjusting dilution factors	15,552,000	15,552,000
Diluted earnings per share	<u>1,482</u>	<u>1,450</u>

## VII. OBJECTIVES AND FINANCIAL RISKS MANAGEMENT POLICIES

Major risk of financial instruments include market risk, credit risk and liquidity risk.

The Board of Management considers the application of management policies for the above risks as follows:

## 1. Market Risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in market prices. There are three market risks: interest rate risk, foreign exchange risk and other price risks, for example risk of stock price. Financial instruments affected by market risk include deposits and investments held-to-maturity.

The following sensibility analysis relates to the financial position of the Company as at September 30, 2025, and December 31, 2024.

The sensitivity analysis has been prepared on the basis that the amount of net debt, the ratio of fixed to floating interest rates of the debt and the proportion of financial instruments in foreign currencies are all constant.

When calculating the sensibility analysis, the Board of General Directors assumes that the sensibility of available-for-sale liability in the balance sheet and related items in the income statement is affected by changes in the assumption of corresponding market risks. This analysis is based on the financial assets and liabilities that the Company held as at September 30, 2025 and December 31, 2024.

## 1.1. Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to the changes in market prices. Market risks due to change in interest rate of the Company mainly relate to: borrowings and liabilities, cash and short-term deposits.

The Company manages the interest rate risk by analyzing the competition status in the market in order to apply the interest rate that brings benefits to the Company and still in the limit of its risk management.

*Sensibility to interest rate*

The sensitivity of the Company's cash and short-term deposits to changes that may occur at reasonable level in the interest rate is illustrated as follows:

Assuming other variables remain unchanged, the fluctuations in interest rates on cash and short-term deposits with floating interest rates makes impact on the the Company's profit before tax as follows:



## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

*Interest rate sensitivity*

	<i>Increase (+)/ decrease (-) of basis points</i>	<i>Influences on profit before tax</i>
<b>First 9 months of 2025</b>		
VND	+100	1,709,873,004
VND	-100	(1,709,873,004)
USD	+100	24,578,286
USD	-100	(24,578,286)
EUR	+100	6,835,176
EUR	-100	(6,835,176)
<b>First 9 months of 2024</b>		
VND	100	1,708,555,656
VND	-100	(1,708,555,656)
USD	100	23,955,672
USD	-100	(23,955,672)
EUR	+100	5,906,840
EUR	-100	(5,906,840)

Increase/decrease of basic points being used to analyze the sensibility to the interest rate is assumed on the basis of observable conditions of current market. These conditions show that the fluctuation is insignificantly greater than prior periods.

**1.2. Foreign exchange risk**

Foreign exchange risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to the changes in exchange rate. The Company bears risks due to changes in the exchange rate of the currencies other than VND related directly to the Company's business.

The Company manages foreign exchange risk by considering current and expected market status when it outlines plans for future transactions in foreign currencies. The Company does not use any derivative instruments to prevent foreign exchange risks.

*Sensibility to interest rate*

The Company does not analyze the sensibility to the foreign currencies since change in the foreign currencies at the reporting date is insignificant.

**2. Credit risk**

Credit risk is the risk due to the uncertainty in a counterparty's ability to meet its obligations causing the financial loss. The Company bears credit risks from production and doing business activities (mainly trade receivables) and from its financial activities including deposits, foreign exchange transactions and other financial instruments.

*Trade receivables*

The Company minimizes the credit risk by only doing business with entities who have good financial capacity and closely keeping track of the liabilities to speed up the recovery of debts. On the basis of this method and receivables related to different customers, the credit risk does not concentrate on a certain customer.

*Deposit*

The Company mainly maintains deposits in big and prestigious banks in Vietnam. The Company realized that the concentration level of credit exposure to deposits is low.

The Company's Board of Management assesses that most of the financial assets are current and not impaired because these financial assets are related to receivables from reputable and solvent customers, except for overdue and/or impaired receivables presented in the following table:

## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

## 2. Credit risk (cont.)

	Not overdue		Overdue	
	Not impaired	Impaired	Not impaired	Impaired
<b>Sep. 30, 2025</b>				
Under 90 days	2,127,089,055	-	-	-
91-180 days	-	-	-	-
>181 days	-	-	-	1,366,305,133
<b>Total net value</b>	<b>2,127,089,055</b>	<b>-</b>	<b>-</b>	<b>1,366,305,133</b>
Provision for devaluation	-	-	-	(1,315,933,374)
<b>Net value</b>	<b>2,127,089,055</b>	<b>-</b>	<b>-</b>	<b>50,371,759</b>
<b>Dec. 31, 2024</b>				
Under 90 days	2,720,295,798	-	-	-
91-180 days	-	-	-	-
>181 days	-	-	-	1,366,305,133
<b>Total net value</b>	<b>2,720,295,798</b>	<b>-</b>	<b>-</b>	<b>1,366,305,133</b>
Provision for devaluation	-	-	-	(1,315,933,374)
<b>Net value</b>	<b>2,720,295,798</b>	<b>-</b>	<b>-</b>	<b>50,371,759</b>

## 3. Liquidity risk

Liquidity risk is the risk that arises from the difficulty in fulfilling financial obligations due to lack of capital. The liquidity risk of the Company mainly arises from difference of maturity of the financial assets and liabilities.

The Company supervises liquidity risk by maintaining an amount of cash, cash equivalents and borrowings from banks at the level that the Board of Management considers sufficient to satisfy the Company's activities and minimize the influence of changes in cash flows.

The following table summarizes liquidity deadline of the Company's financial liabilities on the basis of estimated payments in accordance with contract which are not discounted:

<b>Sep. 30, 2025</b>	<b>Under 1 year</b>	<b>From 1-5 years</b>	<b>Over 5 years</b>	<b>Total</b>
Trade payables	54,756,038,646	-	-	54,756,038,646
Other payables and accrued expenses	3,592,443,989	-	-	3,592,443,989
<b>Total</b>	<b>58,348,482,635</b>	<b>-</b>	<b>-</b>	<b>58,348,482,635</b>
<b>Dec. 31, 2024</b>	<b>Under 1 year</b>	<b>From 1-5 years</b>	<b>Over 5 years</b>	<b>Total</b>
Trade payables	43,147,713,160	-	-	43,147,713,160
Other payables and accrued expenses	3,527,369,273	-	-	3,527,369,273
<b>Total</b>	<b>46,675,082,433</b>	<b>-</b>	<b>-</b>	<b>46,675,082,433</b>

The company has adequate access to capital and debts due within 12 months will be paid on time.

## VIII. FINANCIAL ASSETS AND LIABILITIES

See Page 31.

The fair value of financial assets and financial liabilities is stated at the value that the financial instruments are convertible in present transaction among partners, except for compulsory sale or disposal.

The Company uses the following methods and assumptions to estimate the fair value:



**NOTES TO THE FINANCIAL STATEMENTS**

Q3 2025

Unit: VND

The fair value of cash on hand and short-term deposits, trade receivables, trade payables and other short-term liabilities is equivalent to the book value of these items because these instruments are in short-term.

Except for the above-mentioned items, the fair value of financial assets and financial liabilities has not been valued and determined officially as at September 30, 2025, and December 31, 2024. However, the Board of Management has assessed that the fair value of financial assets and liabilities is not significantly different from the book value at the fiscal year end.

**IX. ADDITIONAL INFORMATION FOR ITEMS IN THE CASH FLOW STATEMENT:** Not applicable.**X. OTHER INFORMATION****1. Contingent liabilities, commitments and other information**

The Company signed the land lease contract No. 6389/HD-TNMT-QHSDD dated August 8, 2008, with the People's Committee of Ho Chi Minh City for a land area of 5,000 square meters located on Nguyen Dong Chi Street, Tan My Ward, Ho Chi Minh City. The lease term is until May 2, 2053. The annual land rental payment is made according to the regulated unit price.

**2. Subsequent events**

There are no significant events occurring since the end of the first six-month accounting period 2025 that require adjustments or notes in the financial statements.

**3. Related parties transactions**

Related parties to the Company include: key management members, individuals related to key management members and other related parties.

- During the period, the Company did not generate sales transactions and provide services, nor did not have other transactions with key management members and individuals related to these management members.

- As at September 30, 2025, the Company has no debt with key management members and individuals related to these members.

- The income of the Board of Directors and the Board of Management is the total income including salary, bonus, allowance from the management position and achievements from directly participating in medical examination and treatment activities, details as follows:

	Position	Q3 2025	Q3 2024
<b>Salary and bonus of the Board of Directors</b>		<b>689,558,187</b>	<b>551,609,469</b>
Dr. Nguyen Ngoc Chieu, MD, PhD	Chairman	371,609,469	371,609,469
Dr. Chu Trong Hiep, MD, PhD	Member	92,307,692	45,000,000
Pham Anh Dung, MBA	Member	66,666,667	45,000,000
Dr. Pham Bich Xuan, Specialist Level 1	Member	66,666,667	45,000,000
Dr. Phan Kim Phuong, MSc	Member	92,307,692	45,000,000
<b>Salary and bonus of the Board of Supervisors</b>		<b>138,000,000</b>	<b>153,000,000</b>
Nguyen Duc Tuan, BA	Chief Supervisor (Appointed on Apr. 25, 2025)	79,658,089	-
Ms. Bui Thuy Kieu	Member	48,000,000	39,000,000
Dr. Le Thi Huyen Trang	Member	45,000,000	36,000,000
Vuong Thi Quynh Anh, BA	Chief Supervisor (end of term on Apr. 25, 2025)	-	42,000,000



## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

<b>Salary and bonus of Board of Management</b>		<b>5,911,997,896</b>	<b>5,776,033,593</b>
<i>Dr. Do Van Buu Dan,</i> <i>Specialist Level 1</i>	<i>General Director</i>	<i>698,396,805</i>	<i>622,785,717</i>
<i>Dr. Ton That Minh, MD, PhD</i>	<i>Hospital Director</i>	<i>1,216,004,732</i>	<i>1,249,753,462</i>
<i>Dr. Chu Trong Hiep, MD, PhD</i>	<i>Director of Cardiac Surgery</i>	<i>755,076,986</i>	<i>733,708,243</i>
<i>Dr. Dinh Duc Huy, MD, PhD</i>	<i>Director of Internal Cardiology</i>	<i>621,120,497</i>	<i>608,256,199</i>
<i>Assoc. Prof. Dr. Nguyen Thi Bich Dao, MD, PhD</i>	<i>Deputy Director of Endocrinology and Nutrition</i>	<i>295,527,278</i>	<i>291,503,028</i>
<i>Dr. Nguyen Huynh Khuong, MSc</i>	<i>Deputy Director of Interventional Cardiology and Vascular Diseases</i>	<i>515,713,237</i>	<i>484,484,848</i>
<i>Dr. Ly Huy Khanh, Specialist Level 2</i>	<i>Deputy Director of General Planning</i>	<i>244,751,477</i>	<i>249,463,154</i>
<i>Dr. Ngo Thi Kim Anh, MSc</i>	<i>Deputy Director of Outpatient Examination and Treatment</i>	<i>286,403,840</i>	<i>268,198,435</i>
<i>Dr. Thai Minh Thien, Specialist Level 2</i>	<i>Deputy Director of Emergency and Cardiovascular Intensive Care</i>	<i>391,519,374</i>	<i>411,396,891</i>
<i>Nguyen Ngoc An Khoi, BA</i>	<i>Deputy Director of Brand Development</i>	<i>200,962,246</i>	<i>194,120,651</i>
<i>Nguyen Ngoc Nhu Anh, BA</i>	<i>Deputy Director of Administration (appointed on May 16, 2024)</i>	<i>174,952,267</i>	<i>165,999,859</i>
<i>Tran Thi Thanh Nhan, BA</i>	<i>Deputy Director of Administration - Human Resources Organization</i>	<i>204,064,246</i>	<i>196,622,651</i>
<i>Phan Thi Thanh Nga, MBA</i>	<i>Chief Financial Officer and concurrently Chief Accountant</i>	<i>307,504,912</i>	<i>299,740,455</i>

**4. Presentation of segment asset, revenue and operating result**

The Board of Management of the Company defines that the issuing managerial decisions of the Company are mainly based on types of products, services that the Company provides, not on the geographical region where the Company provides its products, services. Therefore, the major report is by business sector.

**4.1. Major segment reporting: by business sector**

The Company reports its activities by business segments: the pharmaceutical sales segment, the medical examination and treatment services segment, and other segments. The Company analyzes revenue and cost of goods sold by business segment as follows:

**a. Segment report by business sector for Q3 2025**

	<b>Segment of Medical examinations and treatments</b>	<b>Segment of drug sales</b>	<b>Total</b>
Net revenue	152,508,641,342	58,532,511,728	<b>211,041,153,070</b>
Cost of goods sold	112,964,572,132	51,663,127,082	<b>164,627,699,214</b>
Gross profit	39,544,069,210	6,869,384,646	<b>46,413,453,856</b>



## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

## b. Segment report by business sector for Q3 2024

	Segment of Medical examinations and treatments	Segment of drug sales	Total
Net revenue	148,566,943,282	50,997,391,120	199,564,334,402
Cost of goods sold	109,258,573,291	43,975,631,323	153,234,204,614
Gross profit	39,308,369,991	7,021,759,797	46,330,129,788

## 4.2. Minor segment reporting by: geographical region

The Company operates solely at its headquarters located in Ho Chi Minh City and has no branches. Therefore, the Company does not present notes for segment reporting by geographical region.

## 5. Information on going-concern operation: The Company will continue its operation in the future.

HCM City, Oct 18, 2025

PREPARED BY - THE CHIEF ACCOUNTANT



Phan Thi Thanh Nga, MBA

CHAIRMAN OF THE BOARD OF DIRECTORS



Dr. Nguyen Ngoc Chieu, MD, PhD

**NOTES TO THE FINANCIAL STATEMENTS**

Q3 2025

Unit: VND

**V. 6. Overdue debts with provisions**

	Sep. 30, 2025			Jan. 01, 2025		
	Original cost	Provision amount	Overdue time	Original cost	Provision amount	Overdue time
<b>Other customers</b>						
<b>Short-term receivables</b>	<b>1,366,305,133</b>	<b>1,315,933,374</b>		<b>1,366,305,133</b>	<b>1,315,933,374</b>	
Dang Van Van	110,539,626	110,539,626	Over 3 years	110,539,626	110,539,626	Over 3 years
Dum Nan	262,697,893	262,697,893	Over 3 years	262,697,893	262,697,893	Over 3 years
Nguyen Ngoc Khanh Linh	198,304,565	198,304,565	Over 3 years	198,304,565	198,304,565	Over 3 years
Nguyen Cao Bach	297,349,715	297,349,715	Over 3 years	297,349,715	297,349,715	Over 3 years
Van Thi Hong Tam	129,525,751	129,525,751	Over 3 years	129,525,751	129,525,751	Over 3 years
Nguyen Thi Hoang My	100,743,518	50,371,759	Over 1 year	100,743,518	50,371,759	Over 1 year
Other overdue receivables	267,144,065	267,144,065	Over 3 years	267,144,065	267,144,065	Over 3 years
<b>Total</b>	<b>1,366,305,133</b>	<b>1,315,933,374</b>		<b>1,366,305,133</b>	<b>1,315,933,374</b>	



## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

## V8. Tangible fixed assets

Items	Buildings & structures	Machinery & equipment	Transportation & facilities	Office equipment	Others	Total
<b>Original cost</b>						
Balance as at Jan. 01, 2025	140,870,891,435	242,270,065,776	7,317,333,068	2,352,866,014	551,740,761	<b>393,362,897,054</b>
New purchases	-	26,110,743,636	-	317,500,000	368,000,000	<b>26,796,243,636</b>
Disposal, sale	-	(15,541,205,988)	-	-	-	<b>(15,541,205,988)</b>
Increase, decrease due to asset reclassification	470,700,000	(470,700,000)	-	-	-	<b>-</b>
Balance as at Sep. 30, 2025	141,341,591,435	252,368,903,424	7,317,333,068	2,670,366,014	919,740,761	<b>404,617,934,702</b>
<b>Accumulated depreciation</b>						
Balance as at Jan. 01, 2025	74,449,116,056	171,289,460,300	4,818,777,627	1,571,443,338	530,404,773	<b>252,659,202,094</b>
Charge for the period	3,487,029,210	10,866,054,302	427,354,593	165,450,636	196,103,957	<b>15,141,992,698</b>
Disposal, sale	-	(15,442,655,821)	-	-	-	<b>(15,442,655,821)</b>
Increase, decrease due to asset reclassification	23,535,000	(23,535,000)	-	-	-	<b>-</b>
Balance as at Sep. 30, 2025	77,959,680,266	166,689,323,781	5,246,132,220	1,736,893,974	726,508,730	<b>252,358,538,971</b>
<b>Net book value</b>						
Balance as at Jan. 01, 2025	66,421,775,379	70,980,605,476	2,498,555,441	781,422,676	21,335,988	<b>140,703,694,960</b>
Balance as at Sep. 30, 2025	63,381,911,169	85,679,579,643	2,071,200,848	933,472,040	193,232,031	<b>152,259,395,731</b>

\* Ending net book value of tangible fixed assets pledged/mortgaged as loan security: Not incurred.

\* Ending original costs of tangible fixed assets-fully depreciated but still in use: VND 90,456,526,409.

\* Ending original costs of tangible fixed assets-waiting to be disposed: Not incurred.

\* Commitments on tangible fixed assets acquisitions, sales of large value: Not incurred.

\* Other changes in tangible fixed assets: Not incurred.

## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

## V.16. Owners' equity

## a. Comparison schedule for changes in Owner's Equity

Items	Owners' paid-in capital	Share premium	Investment and Development Fund	Other funds	Undistributed earnings	Total
<b>Balance as at Jan. 01, 2024</b>	<b>155,520,000,000</b>	<b>1,407,488,000</b>	<b>16,603,467,737</b>	<b>1,845,698,259</b>	<b>127,269,610,262</b>	<b>302,646,264,258</b>
Profit	-	-	-	-	58,168,318,395	<b>58,168,318,395</b>
Appropriation to funds	-	-	-	2,094,059,462	(5,594,059,462)	<b>(3,500,000,000)</b>
Dividends distributed	-	-	-	-	(54,022,736,000)	<b>(54,022,736,000)</b>
Other reduction	-	-	-	(2,014,677,875)	-	<b>(2,014,677,875)</b>
<b>Balance as at Sep. 30, 2024</b>	<b>155,520,000,000</b>	<b>1,407,488,000</b>	<b>16,603,467,737</b>	<b>1,925,079,846</b>	<b>125,821,133,195</b>	<b>301,277,168,778</b>
<b>Balance as at Jan. 01, 2025</b>	<b>155,520,000,000</b>	<b>1,407,488,000</b>	<b>16,603,467,737</b>	<b>1,855,123,878</b>	<b>148,731,346,805</b>	<b>324,117,426,420</b>
Profit	-	-	-	-	70,106,059,124	<b>70,106,059,124</b>
Appropriation to funds	-	-	-	2,523,818,129	(6,023,818,129)	<b>(3,500,000,000)</b>
Dividends distributed (*)	-	-	-	-	(54,022,736,000)	<b>(54,022,736,000)</b>
Other reduction (*)	-	-	-	(2,083,000,000)	-	<b>(2,083,000,000)</b>
<b>Balance as at Sep. 30, 2025</b>	<b>155,520,000,000</b>	<b>1,407,488,000</b>	<b>16,603,467,737</b>	<b>2,295,942,007</b>	<b>158,790,851,800</b>	<b>334,617,749,544</b>

First 9 months of 2025

**- Appropriation to funds**

+ Provisional allocation to the operating fund of the Board of Directors and the Board of Supervisors for 2025.

2,523,818,129

+ Provisional allocation to the bonus and welfare fund for 2025 according to the profit distribution plan

3,500,000,000

**6,023,818,129****- Dividend distribution**

+ Distribution of the second dividend payment for 2024 according to Resolution No. VII.05/NQ-BOD dated December 26, 2024

16,370,526,000

+ Distribution of the third dividend payment for 2024 according to Resolution No. 01.2025/NQ-GMS dated April 25, 2025

21,281,684,000

+ First Interim Dividend for 2025 Based on Resolution No. VII.08.01/NQ-HĐQT dated July 15, 2025

16,370,526,000

**54,022,736,000**



## NOTES TO THE FINANCIAL STATEMENTS

Q3 2025

Unit: VND

## VIII. FINANCIAL ASSETS AND LIABILITIES

The following table specifies book value and fair value of the financial instruments presented in the financial statements.

	Book value				Fair value	
	Sep. 30, 2025		Dec. 31, 2024		Sep. 30, 2025	Dec. 31, 2024
	Amount	Provision	Amount	Provision	Amount	Provision
<b>Financial assets</b>						
- Trade receivables	3,493,394,188	(1,315,933,374)	4,086,600,931	(1,315,933,374)	2,177,460,814	3,719,883,542
- Other receivables	20,443,302,309	-	11,182,729,220	-	20,443,302,309	11,182,729,220
- Cash and Cash equivalents	107,051,641,885	-	76,764,812,048	-	107,051,641,885	76,764,812,048
- Held-to-maturity investments	67,077,004,732	-	97,077,004,732	-	67,077,004,732	97,077,004,732
<b>TOTAL</b>	<b>198,065,343,114</b>	<b>(1,315,933,374)</b>	<b>189,111,146,931</b>	<b>(1,315,933,374)</b>	<b>196,749,409,740</b>	<b>188,744,429,542</b>
<b>Financial liabilities</b>						
- Trade payables	54,756,038,646	-	43,147,713,160	-	54,756,038,646	43,147,713,160
- Other payables and accrued expenses	3,592,443,989	-	3,527,369,273	-	3,592,443,989	3,527,369,273
<b>TOTAL</b>	<b>58,348,482,635</b>	<b>-</b>	<b>46,675,082,433</b>	<b>-</b>	<b>58,348,482,635</b>	<b>46,675,082,433</b>